REGENERON PHARMACEUTICALS, INC.

CIK 0000872589 · TARRYTOWN, NY · Quarter end: 2026-06-30 · Filed on: 2026-08-07 · Open the SEC source ↗

REGENERON PHARMACEUTICALS, INC. reported 3 positions worth $177.2M as of June 30, 2026 (13F filed August 7, 2026). Largest holding: PBLS (64.4%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.

$177.2M

2026 Q2

Positions

Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.

100.0%

Est. Net Flow (Q)

—

2026 Q2

Positions Changes Mix History BacktestPRO

3 positions shown

#	Symbol	Company	Type	Value ↓	% Port.	Shares	1Y	YTD
▸ 1	PBLS	Parabilis Medicines, Inc.	SH	$114.0M	64.35%	4,166,666	—	—
▸ 2	NTLA	Intellia Therapeutics, Inc.	SH	$62.7M	35.35%	3,702,995	—	—
▸ 3	ACET	Adicet Bio, Inc.	SH	$522.8K	0.29%	60,511	—	—

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does REGENERON PHARMACEUTICALS, INC. hold as of Q2 2026?

REGENERON PHARMACEUTICALS, INC. reported 3 positions worth $177.2M in its Q2 2026 13F filing. Largest positions: PBLS (64.4%), NTLA (35.4%) and ACET (0.3%).

What did REGENERON PHARMACEUTICALS, INC. buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did REGENERON PHARMACEUTICALS, INC. sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.